Therapix Announces Product License for CannAmide, a Non-Opiate Pain Relief

Therapix Biosciences is developing cannabis-based treatments and recently announced the release of a product license for Palmitoylethanolamide, or PEA, an oral tablet called CannAmide. Health Canada’s Natural and Non-prescription Health Products Directorate recommends it as an anti-inflammatory as well as to relieve chronic pain. The tablet is made of 400mg PEA and is recommended to take 1-3 times a day. Chronic pain affects 38% of people around the world and according to the WHO, half of the conditions responsible for living with a disability involving the presence of pain.

CannAmide now offers a safe and non-opiate option for pain relief. It works by regulating the endocannabinoid levels by enhancing receptor sensitivity. It is considered safe to use as it has little to no concern of abuse. It does, however, have a low solubility in terms of an analgesic. CannAmide is unique as it offers an immediate release to improve bioavailability. Therapix guarantees the quality and consistency of the product and is a huge win for the company. It is also a result of the partnership between Therapix and Destiny. Destiny Bioscience offers the entourage effect of botanical and endogenous cannabinoids.

The companies are thrilled with the approved product license and it bodes well for the future of their partnership. Most importantly, it demonstrates the progressive movement towards natural and non-pharmaceutical forms of pain treatment and management.